Management of Cardiogenic Shock

First-Line Management Approach

The European Society of Cardiology recommends initial management with fluid challenge (250 mL/10 min) if clinically indicated, followed by an inotropic agent if systolic blood pressure remains <90 mmHg 1, 2
Norepinephrine is recommended as the preferred vasopressor when the combination of an inotropic agent and fluid challenge fails to restore adequate blood pressure and organ perfusion 1, 3, 2
Dobutamine is the first-line inotropic agent for increasing cardiac output in cardiogenic shock, according to the European Journal of Heart Failure 4

Norepinephrine should be administered through a central line when inotropic therapy fails to restore systolic blood pressure >90 mmHg with persistent signs of organ hypoperfusion 1, 3, 2
Vasopressors should be used with caution in cardiogenic shock as it is usually associated with high systemic vascular resistance 1, 3
All vasopressors should be discontinued as soon as possible once hemodynamic stability is achieved 1, 3, 2

The European Society of Cardiology explicitly states that epinephrine is not recommended as an inotrope or vasopressor in cardiogenic shock 1, 3, 2
Epinephrine should be restricted to use as rescue therapy in cardiac arrest only 1, 3, 2

Levosimendan may be considered as an alternative inotrope, especially in patients on beta-blocker therapy, as its inotropic effect is independent of beta-adrenergic stimulation 1, 3, 4
Mechanical circulatory support should be considered rather than combining multiple inotropes 4

Continuous monitoring of organ perfusion markers is essential, including urine output, lactate clearance, mental status, and mixed venous oxygen saturation 5, 4
Invasive hemodynamic monitoring with an arterial line is recommended for all patients with cardiogenic shock 5, 4
Treatment targets should include SBP >90 mmHg and cardiac index >2 L/min/m² 5

All inotropes should be used at the lowest possible doses for the shortest duration due to their propensity to increase myocardial oxygen demand and risk of arrhythmias 5
Mechanical circulatory support should be considered early for potentially reversible causes of acute heart failure as a bridge to treatment response 1, 2

The European Society of Cardiology recommends dopamine for patients with acute decompensated heart failure who present with systolic blood pressure <90 mmHg and signs of hypoperfusion, but only after dobutamine has been considered as the preferred first-line inotrope 6
Dopamine should be used specifically when systolic blood pressure is <90 mmHg with peripheral hypoperfusion that is refractory to diuretics and vasodilators 6, 7, 8
Dopamine's effects are highly dose-dependent, which determines its clinical utility, with low-dose (<3 mcg/kg/min) historically promoted for "renal protection" but recent evidence showing no benefit 6, 9, 10
Moderate-dose dopamine (3-5 mcg/kg/min) provides inotropic support through β-adrenergic stimulation, increasing cardiac output and myocardial contractility, and is the therapeutic range for heart failure with hypotension 6, 9, 10
High-dose dopamine (>5 mcg/kg/min) activates α-adrenergic receptors causing vasoconstriction, which increases systemic vascular resistance and may be deleterious in heart failure 6, 7, 9

The European Society of Cardiology guidelines explicitly recommend dobutamine as first-line for increasing cardiac output in cardiogenic shock, with dopamine considered only if the patient has significant bradycardia or blood pressure support is needed beyond pure inotropic effect 10
Dopamine increases myocardial oxygen demand and arrhythmia risk, and should be used at the lowest effective dose for the shortest duration, with monitoring for tachycardia and new arrhythmias 6, 7, 8, 10
Dopamine may cause hypoxemia, and oxygen saturation should be monitored with supplemental oxygen provided as needed 6
Tolerance to dopamine develops after 24-48 hours, and infusions should be tapered gradually while optimizing oral therapy 9, 10

In cardiogenic shock after myocardial infarction, dopamine is preferred initially over dobutamine when systemic hypotension is prominent, but dobutamine is preferred once blood pressure stabilizes 6, 10
Levosimendan may be considered as an alternative to dopamine, especially in beta-blocked patients 6, 10